TBX19

Across TCGA pan-cancer cohorts, TBX19 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TBX19 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher TBX19 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TBX19 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KICH, BRCA, and LIHC are the cancer types where TBX19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BRCA	OS	Median	IV	0.106	0.791	<.001	12	view →
LIHC	OS	Median	II,III,IV	0.118	0.716	.003	12	view →
SKCM	OS	Median	All	0.345	0.784	.006	11	view →
LGG	DFS	Median	All	0.192	0.738	.005	6	view →
UCEC	OS	Median	All	0.964	0.659	.044	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TBX19–KICH (DFS)

Open the KICH breakdown →